Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASSERT: odevixibat in Alagille syndrome
NL-OMON51192Phase 3Active, not recruiting
- Sponsor
- Albireo Pharma
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alagille syndrome (ALGS) comparing Odevixibat with Placebo (2 arms). Primary endpoint: Change from baseline in scratching to Month 6. Started Dec 2021; status: active, not recruiting.
02
Drugs
odevixibat
03
Conditions
Alagille syndrome (ALGS)
Beyond the preview
Go deeper on NL-OMON51192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51192.